New Clinical Trial for Treatment of Mesothelioma
Morphotek has announced the beginning of a phase II clinical trial investigating the efficacy of the monoclonal antibody MORAb-009 for the treatment of mesothelioma. The study will evaluate progression-free survival in patients with advanced pleural mesothelioma who are being receiving MORAb-009 in combination with the standard mesothelioma treatment regimen, pemetrexed + cisplatin. The study will also analyze the “safety and anti-tumor activity of MORAb-009 as determined by objective response rate.” Morphotek plans on enrolling more than eighty individuals into the study, which is being conducted at multiple treatment centers around the word.
MORAb-009 is a monoclonal antibody whose mechanism of action inhibits the expression of mesothelin, which is a cell-surface protein highly expressed in mesothelioma, pancreatic cancer and a number of other malignant conditions.
